ZYDUS LIFESCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 |
| EBITDA (ex other income) | 3,453 | 3,256 | 5,370 | 6,839 | 7,959 |
| margin % | 22.6 | 18.9 | 27.5 | 29.4 | 29.3 |
| Owners' profit | 4,487 | 1,960 | 113 | 147 | 5,040 |
| EPS, as reported (₹) | 43.84 | 19.30 | 38.14 | 44.97 | 50.09 |
| ROE % · ROCE % | 24.2 · 14.8 | 10.6 · 13.4 | 18.0 · 20.4 | 17.7 · 22.0 | 17.3 · 19.2 |
| Debt / equity (x) | 0.22 | 0.06 | 0.03 | 0.12 | 0.40 |
| Cash from operations | 2,078 | 2,689 | 3,228 | 6,777 | 2,117 |
| Capex | (1,203) | (1,031) | (907) | (1,713) | (3,394) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,237 | 5,269 | 6,528 | 6,574 | 6,123 | 6,865 | 7,587 | 8,017 |
| Profit before tax | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 | 1,353 | 1,660 | 1,307 |
| Net profit | 920 | 1,026 | 1,244 | 1,521 | 1,239 | 1,023 | 1,341 | 990 |
| EPS (₹) | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 | 10.36 | 12.65 | 9.35 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 22,867 | 84.2 |
| Consumer products | 1,483 | 5.5 |
| Medical technologies | 328 | 1.2 |
| Consumer Products | 2,471 | 9.1 |
| Total, before eliminations | 27,148 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · CRISIL reaffirms AAA rating on Zydus Lifesciences bank facilities and debt | credit debt | medium | — | — |
| 11 Sept 2026 · Zydus Lifesciences to participate in J.P. Morgan India Conference 2026 | board shareholder meetings | low | — | — |
| 9 Sept 2026 · Newspaper publication for lost share certificates | compliance | minimal | — | — |
| 5 Sept 2026 · US Subsidiary Settles Generic Drug Pricing Antitrust Case for USD 5.9 Million | regulatory legal | high | — | — |
| 1 Sept 2026 · Zydus Lifesciences 31st AGM transcript filed; FY27 high-teen growth guided | investor communications | medium | — | — |
| 31 Aug 2026 · Zydus Lifesciences announces positive Phase II(b) trial results for Saroglitazar Mg in MASH | compliance | low | — | — |
| 26 Aug 2026 · Zydus sets up wholly owned treasury subsidiary in GIFT City | strategic transactions | medium | — | — |
| 25 Aug 2026 · ESG rating upgraded to 66 by CRISIL, now in 'strong' category | credit debt | medium | — | — |
| 24 Aug 2026 · Zydus: 32,577 promoter group shares transmitted via inheritance | ownership changes | low | — | — |
| 23 Aug 2026 · Zydus Lifesciences Investor Presentation for Aug 2026 Conference | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 36.5 |
| 5.26 |
| 23.7 |
| 13.7 |
| 17.5 |
| 11.8 |
| 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD ◆ | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 24.9 | 28.9 | 72 of 169 | 58% |
| P/B | 3.8 | 3.3 | 93 of 163 | 43% |
| ROCE | 18.0 | 10.8 | 44 of 183 | 76% |
| ROE | 17.3 | 10.4 | 35 of 171 | 80% |
| Debt / Equity | 0.4 | 0.1 | 129 of 171 | 25% |
| EBITDA margin | 25.2 | 17.5 | 53 of 165 | 68% |
| Revenue growth | 22.0 | 16.3 | 65 of 161 | 60% |
| Profit growth | (34.9) | 30.9 | 124 of 158 | 22% |
| Market cap | 111686 | 839 | 4 of 182 | 98% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
